Refeeding Syndrome in Oncology: Report of Four Cases

Martin Windpessl, Beate Mayrbaeul, Christian Balding, Gernot Tiefenthaler, Friedrich C. Prischl, Manfred Wallner, Josef Thaler

Abstract
The term refeeding syndrome (RFS) refers to the metabolic perturbations and its attendant complications in subjects who are refed after fasting. The syndrome is characterized by profound shifts of electrolytes and fluids. Its consequences are widespread and sometimes fatal. Patients with malignancies are especially vulnerable due to the presence of multiple comorbidities. We report the course of four patients with malignant or hematological disorders who developed RFS while being treated for their underlying illness. All physicians caring for susceptible patients should be cognizant of the risks of refeeding and treat RFS appropriately to reduce patient morbidity as well as mortality.

Keywords: Refeeding; Hypophosphatemia; Cancer; Oncology; Malnutrition

Introduction
Not widely known outside nutritional support circles, the term refeeding syndrome (RFS) denotes a cascade of metabolic disturbances and clinical symptoms that may develop when previously malnourished patients are refed carbohydrates, whether this is by the oral, enteral or parenteral route [1]. The syndrome is characterized by profound shifts of electrolytes and fluids, with hypophosphatemia constituting the cardinal biochemical feature. Serious cardiac, respiratory and neurologic complications may occur; in extreme cases, these complications may prove fatal [2]. This notwithstanding, protocols aimed at its prevention and management are lacking in many hospitals.

While anorexia nervosa is the modern prototypical predisposing condition, there are many clinical situations in which RFS may occur [1, 3]. Cancer patients undergoing chemotherapy seem particularly vulnerable due to the presence of several comorbidities, both disease- and treatment-related [4, 5]. Therefore, RFS represents an important aspect of supportive oncology. Given its non-specific symptoms, recognizing RFS can be a difficult task. As such, it remains “underdiagnosed and undertreated” [6].

In this case series, we present the clinical course of four patients with malignant or hematological disorders who experienced RFS while being treated for their underlying illness. We aim to raise awareness of this syndrome in physicians involved in nutritional support, provide suggestions for the prevention of RFS and outline treatment strategies, according to the evidence in the literature. We believe that local guidelines should be established. Hospital nutrition teams, where available, may help in this regard.

Case Reports

Case 1
A 35-year-old woman with longstanding rheumatoid arthritis was admitted because of febrile neutropenia, presumably drug-related. Her body mass index (BMI) was 18.3 kg/m². On examination, severe mucositis was apparent. Laboratory results showed an absolute neutropenia and a significant inflammatory response. Electrolytes and renal function were normal on admission (Table 1). A diagnosis of methotrexate-induced neutropenia was made. The patient was isolated and commenced on broad spectrum antibiotic treatment (piperacillin-tazobactam) and a granulocyte-colony stimulating factor was given. As she remained unable to eat, a central line was placed and intravenous nutrition was started at a rate of 18 kcal/kg/day after 10 days of negligible food intake. B-multivitamins were added. The infusion rate was not altered, but within the next 3 days phosphate plummeted to 0.15 mmol/L (normal: 0.7 - 1.3 mmol/L). Edema developed and the patient complained of diffuse abdominal pain. In view of her electrolyte disturbance and fluid retention, a diagnosis of RFS was made. Parenteral phosphate supplementation was prescribed. Nutrition was withheld temporarily and restarted at a slower rate. By hospital day 10, electrolytes had normalized. In parallel, the blood count had recovered and the patient was discharged after 3 weeks.

Case 2
A 69-year-old man with advanced squamous cell carcinoma of the tonsil was admitted for palliative chemotherapy. Within

Manuscript accepted for publication February 13, 2017

*Department of Internal Medicine IV, Klinikum Wels-Grieskirchen, Wels, Austria
*Corresponding Author: Martin Windpessl, Department of Internal Medicine IV, Klinikum Wels-Grieskirchen, Grieskirchnerstrasse 42, 4600 Wels, Austria.
Email: martin.windpessl@klinikum-wegr.at

doi: https://doi.org/10.14740/wjon1007w
the preceding 6 months, he had lost 30% of his usual body weight. His current BMI was 16.9 kg/m². On admission, mild hypomagnesemia was present, otherwise electrolytes were in the normal range (Table 1). A percutaneous endoscopic gastrostomy (PEG) was placed because of dysphagia. On day 5, cetuximab and docetaxel were administered as scheduled. Due to poor wound healing, the feeding tube could not be used immediately and parenteral nutrition via a pre-existing port-a-cath was introduced for 3 days at a daily rate of 24 kcal/kg/day. At that point, he had not eaten properly for 9 days. Subsequently, enteral nutrition was commenced via the PEG at a rate of 24 kcal/kg/day for 5 days. Profound hypophosphatemia developed (nadir 0.27 mmol/L; normal: 0.7 - 1.3 mmol/L) and hypomagnesemia and hypocalcemia worsened concurrently. Within 12 days from admission, marked fluid retention had occurred amounting to a gain of weight of 10 kg. Nutrition was withheld intermittently, parenteral phosphate was administered and feeding was restarted at a slower rate. Except for magnesium, his electrolytes normalized within the following 4 days and he was discharged after 2 weeks.

Case 3

A 66-year-old woman was diagnosed with metastasized squamous cell cancer of the anus and admitted for initiation of palliative chemotherapy. Over the last 4 months, she had lost 12% of weight and her BMI was 20.8 kg/m². After implantation of a port-a-cath, 5-fluorouracil and cisplatin were administered as per protocol. Despite supportive measures, the treatment was poorly tolerated and complicated by prolonged anorexia. Due to severe gingivitis, she had barely eaten for 5 days and parenteral nutrition was prescribed at a rate of 18 kcal/kg/day and left unaltered for the following 4 days. Electrolytes showed typical features of the RFS (Table 1) and the patient complained of generalized languor. After electrolyte supplementation, salt restriction and cautious switch to oral nutrition, her symptoms slowly abated.

Case 4

Five days after his third cycle of chemotherapy (5-fluorouracil/cisplatin) for adenocarcinoma of the esophagus, a 72-year-old man was admitted with severe mucositis. Within 3 months, he had lost 18% of his usual weight and his BMI was 21.9 kg/m² on admission. He had had negligible oral intake for 8 days. Electrolytes were normal but marked hyperglycaemia was present, deemed due to high dose dexamethasone (Table 1). Insulin sliding-scale was commenced and glucose normalized subsequently. On hospital day 4, the patient became septic and was transferred to the intensive care unit (ICU) for inotropic support and broad cover antibiotic treatment (pipercillin-tazobactam). Whilst on ICU, parenteral nutrition was commenced at a rate of 15 kcal/kg/day for 2 days which triggered a precipitous drop in phosphate. Parenteral phosphate substitution improved values to some extent. After 3 days, he could be transferred back to the normal ward. Parenteral nutrition was restarted at the same rate and continued unchanged for 6 days. In parallel, electrolytes decreased again. Within 1 week, he had gained 9 kg in weight. Edema was present. A diagnosis of RFS was made, possibly aggravated by concurrent sepsis and sodium-containing antibiotics. Electrolytes were substituted aggressively and salt and fluid restriction was implemented. The patient was finally discharged after 3 weeks with normal electrolytes.

The salient laboratory results of all cases are summarized in Table 1. The course of individual serum phosphate levels is depicted in Figure 1.

**Discussion**

The perils of reinstituting nutrition after periods of starvation have been recognized since World War II, with victims of famine being the first documented cases. However, it was only with the advent of widespread nutritional support that this phenomenon has garnered renewed attention. More than 30 years ago, reporting the death of two malnourished patients who were fed “overzealously”, Weinsier and Krumdieck coined the term “refeeding syndrome” [7].

From a pathophysiological view, malnourished patients gradually develop a total body depletion of phosphorous. Insulin levels fall during starvation as the body switches from carbohydrate to fat metabolism. Following the delivery of glucose as part of a feeding regimen, the sudden mount in insulin secretion reverses catabolism to anabolism [8]. Due to the associated transcellular flux of electrolytes and the increased

| Table 1. Laboratory Findings of Four Consecutive Patients With the Refeeding Syndrome |
|-----------------|-----------------|-----------------|-----------------|-----------------|
|                 | Patient 1       | Patient 2       | Patient 3       | Patient 4       |
|                 | A1 B5 C8 D13   | A1 B13 C19 D22 | A1 B8 C10 D15  | A1 B4 C7 D20   |
| Na⁺ (mmol/L)    | 137 142 141 143| 136 127 128 129| 139 129 127 134| 151 157 136 140|
| K⁺ (mmol/L)     | 3.7 3.1 3.7 3.7 | 4.6 3.7 3.4 3.6 | 3.7 3.0 3.5 3.7 | 2.9 2.7 3.2 3.1|
| Ca²⁺ (mmol/L)   | 2.47 2.08 2.04 | 2.33 2.35 2.00 | 1.75 1.64 2.40 | 2.13 2.00 2.30 |
| Mg²⁺ (mmol/L)   | 0.75 0.67 0.71 | 0.84 0.59 0.58 | 0.37 0.40 0.75 | 0.69 0.54 0.66 |
| Cl⁻ (mmol/L)    | 99 110 110 108 | 101 94 94 98   | 1.22 90 92 96  | 116 127 107 107|
| PO₄³⁻ (mmol/L)  | 0.88 0.65 0.15 | 1.05 0.97 0.56 | 0.27 0.61 0.76 | 0.73 0.27 0.68 |

A: admission; B: start of nutritional support; C: phosphate nadir; D: last lab result before discharge. Numbers denote hospital day.
cellular demands, the serum concentration of these agents can fall dramatically. Hypophosphatemia, which constitutes the biochemical hallmark of RFS, is almost universally present [9]. Not surprisingly, in the treatment of diabetic ketoacidosis, analogous metabolic perturbations occur. The insulin surge also enhances fluid and sodium retention, further contributing to morbidity [10]. Concomitant thiamine deficiency can occur and may present as Wernicke encephalopathy [1].

While RFS is typically presented as a single entity, in practice it constitutes a spectrum disorder that occurs under particular circumstances within a high-risk population, i.e., malnourished patients with negligible food intake for several days at the time of refeeding. No unanimously agreed definition exists [11]. Clinical manifestations are related directly to electrolyte and vitamin deficiency but are variable and unpredictable [12]. Cardiac arrhythmias and heart failure are the most dreaded aspects of the RFS. Fluid retention, respiratory failure and neuromuscular problems such as paralysis, seizures and rhabdomyolysis may also occur. Case reports have emphasized the potentially fatal nature of this condition [2, 7].

There is a paucity of data about the incidence of RFS in patients with cancer. However, in a Mexican study, it was reported to be as high as 25% [13]. Individuals with head and neck cancer (HNC) are particularly vulnerable for this phenomenon. A Danish report found an incidence of 20% in HNC patients referred for surgery (n = 54), with a history of previous radiation therapy among the predisposing factors [14]. Likewise, in a Dutch cohort of internal medicine patients (n = 178), sepsis and malignancy conferred the highest risk for the development of RFS [10]. Disease-related malnutrition reportedly occurs in approximately half of oncology patients and is associated with negative outcomes [4, 12, 15]. Pre-existing electrolyte disorders are common in these patients, whether this is paraneoplastic, associated with chemotherapeutic regimens or other com-

| Table 2. | Guideline for the Management of the RFS (Adapted From Refs. [5, 21, 22]) |
|-----------------|------------------------------------------------------------------|
| Identify patients at risk (“Discussion”) |
| Check electrolytes prior to re-alimentation and correct deficiencies |
| Administer thiamine 200 - 300 mg daily |
| Limit salt and fluid intake |
| Start feeding 10 kcal/kg/day and slowly increase over the first week |
| Monitor electrolytes and weight daily |
| If severe hypophosphatemia (< 0.3 mmol/L) develops: give phosphate parenterally* |

*Assuming normal renal function, parenteral phosphate repletion is generally safe with doses up to 45 mmol with infusion rates up to 20 mmol per hour. Individualized frequent checks are recommended (e.g. after 6 and 12 h on day 1) [25].

For detailed recommendations regarding electrolyte substitution, see particularly Ref. [22].
levels slowly to meet full needs within 1 week [21]. At a maximum of 10 kcal/kg/day is recommended, increasing however, in such high-risk patients, starting nutrition support 15 to 24 kcal/kg/day in the respective cases) being delivered. started rather carefully, with only 1,000 kcal/day (ranging from start of nutrition (Table 3) [21]. At first glance, refeeding was ed could have been found to be at high risk of RFS before the Table 2 [5, 21, 22]. By using these criteria, all patients present-

tailed instructions for electrolyte replacement [22]. Both guide-

lines could serve as templates for local protocols as shown in

Clinical Nutrition & Metabolism followed suit with de-

tary for Clinical Nutrition & Metabolism followed suit with de-

by case 2 [16, 17]. Hypophosphatemia can be frequently found in

patients with sepsis, especially in Gram-negative bacteremia

and its extent correlates with illness severity [18]. Electrolyte

disorders such as hypokalemia can also arise as a consequence

of antibiotic therapy. Moreover, sodium-containing antibiotic

regimens such as piperacillin-tazobactam can lead to fluid re-

tention [19]. Therefore, it is often difficult if not impossible to

ascribe biochemical and clinical complications to one of sev-

eral causative factors. As illustrated by case 4, these events

often occur in parallel and should be seen as potentiating each

other rather than causing the RFS singularly.

Timely recognition of patients at risk is crucial before initi-

ating nutritional support. Any patients with negligible food in-

take for more than 5 days should be deemed at risk of develop-

ing refeeding problems [20]. The short nutritional assessment

questionnaire (SNAQ) had a high negative predictive value for

the diagnosis of RFS in one observational study [10]. In 2006,

the British National Institute for Clinical Excellence (NICE)

came up with criteria for identifying patients at risk and offered

treatment strategies and is still considered a useful tool in daily

practice [10, 21]. Of note, a history of recent chemotherapy is

one of several risk factors cited for RFS. In 2013, the Irish Soci-

ety for Clinical Nutrition & Metabolism followed suit with de-

tailed instructions for electrolyte replacement [22]. Both guide-

lines could serve as templates for local protocols as shown in

Table 2 [5, 21, 22]. By using these criteria, all patients present-

ed could have been found to be at high risk of RFS before the

start of nutrition (Table 3) [21]. At first glance, refeeding was

started rather carefully, with only 1,000 kcal/day (ranging from

15 to 24 kcal/kg/day in the respective cases) being delivered.

However, in such high-risk patients, starting nutrition support

at a maximum of 10 kcal/kg/day is recommended, increasing

levels slowly to meet full needs within 1 week [21].

Prior to refeeding, electrolytes should be checked. Thia-
mine is recommended upfront realimentation in at-risk pa-

tients. Gradual introduction of calories particularly over the

first week of refeeding is prudent until the patient is metaboli-

cally stable (“start low and go slow”). Initially, fluid and salt

intake should be conservative because of the propensity to

retain these [23]. As noted, attention needs to be paid to bio-

chemical indices, and electrolytes should be measured daily.

Once overt RFS has developed, caloric intake should be re-
duced, electrolyte abnormalities treated aggressively and extra

B vitamins given.

Despite considerable progress in our understanding of its

pathophysiology over the last decades, RFS remains underdi-

agnosed, causing avoidable morbidity in core patient groups at

risk. The present case series illustrates that cancer patients are

particularly prone for this phenomenon. Because disease- and

treatment-related complications such as electrolyte disturban-
ces and infections often occur in parallel, diagnosis of RFS can

be delayed. Moreover, it is not unusual for chemistry panels

not to include phosphate unless specifically ordered and it is

partly therefore that phosphate has been dubbed a “neglected

electrolyte” [24]. Our experience emphasizes the need for bet-
ter recognition and monitoring.

To summarize, clinical diagnosis of RFS requires vigi-
lance. As stated by Marinella, physicians involved with pro-

viding supportive care to cancer patients ought to be familiar

with this syndrome and its attendant complications to prevent

morbidity and mortality [25].

Conflicts of Interest

The authors have no conflicts of interest.

References

1. Crook MA, Hally V, Panteli JV. The importance of the refeeding syndrome. Nutrition. 2001;17(7-8):632-637.

2. Boateng AA, Sriram K, Meguid MM, Crook M. Refeeding syndrome: treatment considerations based on collective analysis of literature case reports. Nutrition. 2010;26(2):156-167.

3. Mehanna HM, Molechina J, Travis J. Refeeding syndrome: what it is, and how to prevent and treat it. BMJ. 2008;336(7659):1495-1498.

Table 3. NICE Criteria for Identifying Patients at High Risk of Refeeding Problems (Adapted From [21])

|                         | 1   | 2   | 3   | 4   |
|-------------------------|-----|-----|-----|-----|
| One or more of the following: |     |     |     |     |
| BMI < 16 kg/m²           | -   | -   | -   | -   |
| Weight loss > 15% within the last 3 - 6 months | n/a | +   | -   | +   |
| Little or no nutritional intake for more than 10 days | +   | -   | -   | -   |
| Low levels of electrolytes prior to feeding | +   | +   | +   | +   |
| Two or more of the following: |     |     |     |     |
| BMI < 18.5 kg/m²         | +   | +   | -   | -   |
| Weight loss > 10% within the last 3 - 6 months | n/a | +   | +   | +   |
| Little or no nutritional intake for more than 5 days | +   | +   | +   | +   |
| History of alcohol abuse or drugs including chemotherapy | -   | +   | +   | +   |

Numbers 1 - 4: individual patients. +/- denotes presence/absence of a risk factor. n/a: not available.
4. Marinella MA. Refeeding syndrome: an important aspect of supportive oncology. J Support Oncol. 2009;7(1):11-16.
5. Stanga Z, Brunner A, Leuenberger M, Grimble RF, Shenkin A, Allison SP, Lobo DN. Nutrition in clinical practice-the refeeding syndrome: illustrative cases and guidelines for prevention and treatment. Eur J Clin Nutr. 2008;62(6):687-694.
6. Gariballa S. Refeeding syndrome: a potentially fatal condition but remains underdiagnosed and undertreated. Nutrition. 2008;24(6):604-606.
7. Weinsier RL, Krumdieck CL. Death resulting from overzealous total parenteral nutrition: the refeeding syndrome revisited. Am J Clin Nutr. 1981;34(3):393-399.
8. Walmsley RS. Refeeding syndrome: screening, incidence, and treatment during parenteral nutrition. J Gastroenterol Hepatol. 2013;28(Suppl 4):113-117.
9. Kagansky N, Levy S, Koren-Morag N, Berger D, Knobler H. Hypophosphataemia in old patients is associated with the refeeding syndrome and reduced survival. J Intern Med. 2005;257(5):461-468.
10. Kraaijenbrink BV, Lambers WM, Mathus-Vliegen EM, Siegert CE. Incidence of refeeding syndrome in internal medicine patients. Neth J Med. 2016;74(3):116-121.
11. Miller SJ. Death resulting from overzealous total parenteral nutrition: the refeeding syndrome revisited. Nutr Clin Pract. 2008;23(2):166-171.
12. Palesty JA, Dudrick SJ. Cachexia, malnutrition, the refeeding syndrome, and lessons from Goldilocks. Surg Clin North Am. 2011;91(3):653-673.
13. Gonzalez Avila G, Fajardo Rodriguez A, Gonzalez Figueroa E. [The incidence of the refeeding syndrome in cancer patients who receive artificial nutritional treatment]. Nutr Hosp. 1996;11(2):98-101.
14. Rasmussen SO, Kristensen MB, Wessel I, Andersen JR. Incidence and Risk Factors of Refeeding Syndrome in Head and Neck Cancer Patients-An Observational Study. Nutr Cancer. 2016;68(8):1320-1329.
15. Vandebroek AJ, Schrijvers D. Nutritional issues in anti-cancer treatment. Ann Oncol. 2008;19(Suppl 5):v52-55.
16. Rosner MH, Dalkin AC. Electrolyte disorders associated with cancer. Adv Chronic Kidney Dis. 2014;21(1):7-17.
17. Miltiadous G, Christidis D, Kalogirou M, Elisaf M. Causes and mechanisms of acid-base and electrolyte abnormalities in cancer patients. Eur J Intern Med. 2008;19(1):1-7.
18. Geerse DA, Bindels AJ, Kuiper MA, Roos AN, Sproen PE, Schultz MJ. Approach to hypophosphataemia in intensive care units - a nationwide survey. Neth J Med. 2012;70(9):425-430.
19. Zietse R, Zoutendijk R, Hoorn EJ. Fluid, electrolyte and acid-base disorders associated with antibiotic therapy. Nat Rev Nephrol. 2009;5(4):193-202.
20. Crook MA. Refeeding syndrome: problems with definition and management. Nutrition. 2014;30(11-12):1448-1455.
21. National Institute for Clinical Excellence. Nutrition Support for Adults. Clinical Guideline CG32. 2006 Feb 1;1-176. Cited December 2016. Available from URL: http://www.nice.org.uk/nicemedia/live/10978/29981/29981.pdf.
22. Irish Society for Clinical Nutrition & Metabolism. Prevention and Treatment of Refeeding Syndrome in the Acute Care Setting. IrSPEN Guideline 1. November 2013; 1-31. Cited December 2016. Available from URL: http://www.irspen.ie/wp-content/uploads/2013/12/Refeeding-Syndrome-Guideline-Doc.pdf.
23. Brooks MJ, Melnik G. The refeeding syndrome: an approach to understanding its complications and preventing its occurrence. Pharmacotherapy. 1995;15(6):713-726.
24. Workman ML. Magnesium and phosphorus: the neglected electrolytes. AACN Clin Issues Crit Care Nurs. 1992;3(3):655-663.
25. Marinella MA. Refeeding syndrome in cancer patients. Int J Clin Pract. 2008;62(3):460-465.